The influence of chronic treatment with verapamil on plasma atrial natriuretic peptide levels in young and elderly hypertensive patients

Eur J Clin Pharmacol. 1990:39 Suppl 1:S39-40. doi: 10.1007/BF01409206.

Abstract

In a double-blind, placebo-controlled cross-over study, the plasma atrial natriuretic peptide (ANP) levels of nine young and ten elderly hypertensive patients were compared after placebo and after treatment with 120 mg verapamil given three times daily over 4 weeks. During placebo, plasma ANP levels proved to be higher in elderly patients than in young subjects. Chronic treatment with verapamil induced a rise in ANP levels in both young and elderly patients with hypertension.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Atrial Natriuretic Factor / blood*
  • Blood Pressure / drug effects
  • Double-Blind Method
  • Humans
  • Hypertension / blood*
  • Hypertension / drug therapy
  • Middle Aged
  • Time Factors
  • Verapamil / administration & dosage
  • Verapamil / therapeutic use*

Substances

  • Atrial Natriuretic Factor
  • Verapamil